Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase I/II trial to study the effectiveness of temozolomide plus irinotecan in
treating patients who have recurrent malignant glioma.
Phase:
Phase 1
Details
Lead Sponsor:
North American Brain Tumor Consortium Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins